Eliglustat-d15 (tartrate)

An internal standard for the quantification of eliglustat

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥4075.00

3260.00

- +
5mg

￥16175.00

12940.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx22404
CAS: 1884556-84-6
别名: Genz 99067-d15 tartrate
分子式: C23H21D15N2O4.C4H6O6
分子量: 569.7
纯度: >98%
溶解度: DMSO: soluble,Methanol: soluble,Water: soluble
储存: Store at -20°C
库存: 现货

Background

Eliglustat-d₁₅ is intended for use as an internal standard for the quantification of eliglustat by GC- or LC-MS. Eliglustat is an inhibitor of glucosylceramide synthase (IC₅₀ = 40 nM for inhibition of glucosylceramide production in K562 cells).¹ It is selective for glucosylceramide synthase over α-glucosidase I and II, α-1,6-glucosidase, lysosomal glucocerebrosidase, non-lysosomal glucosylceramidase, sucrase, and maltase (IC₅₀s = >10 µM for all). It decreases cell surface levels of the gangliosides GM₁ and GM₃ in K562 and B16/F10 cells with IC₅₀ values of 24 and 29 nM, respectively. Eliglustat (150 mg/kg per day) decreases glucosylceramide levels in the liver and lungs of D409V/null mice, a model of Gaucher disease. Formulations containing eliglustat have been used in the treatment of type 1 Gaucher disease.

1.McEachern, K.A., Fung, J., Komarnitsky, S., et al.A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher diseaseMol. Genet. Metab.91(3)259-267(2007)